(VIANEWS) – MAGNORA (MGN.OL), X-FAB (XFAB.PA), VISTIN PHARMA (VISTN.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. MAGNORA (MGN.OL)
210.1% sales growth and 52.28% return on equity
Magnora ASA operates as a renewable energy development company. It primarily focuses on developing wind and solar photovoltaic (PV) projects. The company also hold license agreements with the Dana Western Isles and Shell Penguins FPSO. It serves oil companies and marine contractors in the United Kingdom, Norway, and Sweden. The company was formerly known as Sevan Marine ASA and changed its name to Magnora ASA in October 2018. Magnora ASA was incorporated in 2001 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, MAGNORA has a trailing twelve months EPS of kr3.95.
PE Ratio
MAGNORA has a trailing twelve months price to earnings ratio of 7.95. Meaning, the purchaser of the share is investing kr7.95 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 52.28%.
More news about MAGNORA.
2. X-FAB (XFAB.PA)
23.3% sales growth and 19.58% return on equity
X-FAB Silicon Foundries SE operates as an analog/mixed-signal semiconductor technology foundry. The company manufactures silicon wafers for automotive, industrial, consumer, medical, and mobile communications, and other applications; and analog/mixed-signal integrated circuits, sensors, and micro-electro-mechanical systems. It also provides manufacturing and design support services for customers that design analog/mixed-signal integrated circuits and other semiconductor devices, as well as engineering and prototyping, outsourcing, technical, and design support services. The company serves integrated device manufacturers, original equipment manufacturers, and fabless semiconductor companies. It operates in Belgium, Germany, the United Kingdom, Austria, France, Switzerland, Denmark, Sweden, Finland, Netherlands, Ireland, Singapore, China, Japan, Thailand, Malaysia, Korea, Taiwan, Hong Kong, New Zealand, the United States, and internationally. The company was founded in 1992 and is based in Tessenderlo, Belgium.
Earnings Per Share
As for profitability, X-FAB has a trailing twelve months EPS of €1.14.
PE Ratio
X-FAB has a trailing twelve months price to earnings ratio of 9.07. Meaning, the purchaser of the share is investing €9.07 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.58%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 24.1%, now sitting on 852.69M for the twelve trailing months.
Sales Growth
X-FAB’s sales growth is 31.6% for the ongoing quarter and 23.3% for the next.
More news about X-FAB.
3. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 16.03% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 23.2. Meaning, the purchaser of the share is investing kr23.2 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.03%.
More news about VISTIN PHARMA.
